Hypercholesterolemia
Conditions
Brief summary
A study to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of the addition of ezetimibe to rosuvastatin compared with doubling dose of rosuvastatin in participants treated with rosuvastatin alone and not at their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal
Interventions
DRUGComparator: rosuvastatin 5 mg + ezetimibe 10 mg
Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
DRUGComparator: rosuvastatin 10 mg
Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
DRUGComparator: rosuvastatin 10 mg + ezetimibe 10 mg
Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
DRUGComparator: rosuvastatin 20 mg
Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* Participant is currently taking a stable dose of lipid lowering agent(s). (if applicable) or is statin naive * Participant is currently taking a stable dose of lipid lowering agent(s). (if is at least moderate high risk for Coronary Heart Disease (CHD)) * Participant is currently taking a stable dose of lipid lowering agent(s). (if is willing to maintain Therapeutic Lifestyle Changes (TLC) / American Diabetes Association(ADA) diet)
Exclusion criteria
* Participant weighs less than 100 lbs (45 kg). * Participant has hypersensitivity or intolerance to ezetimibe, or rosuvastatin or any components of these medications. * If female, participant is pregnant or breastfeeding. * Participant consumes more than 2 alcoholic beverages per day. * Participant has been in a clinical trial within the last 30 days. * Participant has heart problems such as CHF, unstable angina or heart attack. * Participant has type 1 or 2 diabetes and has changed their medication in the last 2 months. * Participant has liver disease. * Participant is Human Immunodeficiency Virus (HIV) positive. * Participant has a history of drug or alcohol abuse in the last year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment | Baseline to 6 weeks | The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment in participants who were administered ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Reached Their Target LDL-C Level | 6 weeks of treatment | Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment. |
| Number of Participants in Each Stratum Who Reached Their Target LDL-C Level | 6 weeks of treatment | Participants in stratum I were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 5 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 10 mg daily for 6 weeks. Participants in stratum II were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 10 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 20 mg daily for 6 weeks. |
| Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum | Baseline to 6 weeks | The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment by stratum I and stratum II in participants who were administered with ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with the doubling of the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks. |
| Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl | 6 weeks of treatment | Participants in stratum I and in stratum II who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe to rosuvastatin (5 or 10 mg)daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg). |
| Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Baseline to 6 weeks | Participants who were analyzed to assess the Total Cholesterol (TC), Triglycerides, High-Density Lipoprotein Cholesterol, Non High-Density Lipoprotein Cholesterol, LDL Cholesterol/HDL Cholesterol, Total Cholesterol/HDL Cholesterol, Non-HDL Cholesterol/HDL Cholesterol, Apolipoprotein B (Apo B), Apolipoprotein A-I (Apo A-I), Apolipoprotein B/Apo A-I, high-sensitivity C-reactive protein (hs-CRP)levels after 6 weeks of treatment. |
| Number of Participants Who Reached the LDL-C Level of <70 mg/dl | 6 weeks of treatment | Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Rosuvastatin 5 mg + Ezetimibe 10 mg Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks. | 99 |
| Rosuvastatin 10 mg Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks. | 98 |
| Rosuvastatin 10 mg + Ezetimibe 10 mg Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks. | 122 |
| Rosuvastatin 20 mg Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks. | 121 |
| Total | 440 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 3 | 0 | 2 | 1 |
| Overall Study | Lost to Follow-up | 1 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 1 | 2 |
Baseline characteristics
| Characteristic | Rosuvastatin 5 mg + Ezetimibe 10 mg | Rosuvastatin 10 mg | Rosuvastatin 10 mg + Ezetimibe 10 mg | Rosuvastatin 20 mg | Total |
|---|---|---|---|---|---|
| Age, Customized < 65 years | 63 participants | 62 participants | 71 participants | 71 participants | 267 participants |
| Age, Customized ≥ 65 years | 36 participants | 36 participants | 51 participants | 50 participants | 173 participants |
| Sex: Female, Male Female | 35 Participants | 40 Participants | 56 Participants | 37 Participants | 168 Participants |
| Sex: Female, Male Male | 64 Participants | 58 Participants | 66 Participants | 84 Participants | 272 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 99 | 0 / 98 | 0 / 122 | 0 / 121 |
| serious Total, serious adverse events | 0 / 99 | 1 / 98 | 0 / 122 | 1 / 121 |
Outcome results
Primary
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment
The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment in participants who were administered ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
Time frame: Baseline to 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment | -21.57 percent change | Standard Deviation 25.09 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment | -5.58 percent change | Standard Deviation 25.42 |
p-value: <0.00195% CI: [-19.89, -10.6]Longitudinal Data Analysis (LDA)
Secondary
Number of Participants in Each Stratum Who Reached Their Target LDL-C Level
Participants in stratum I were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 5 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 10 mg daily for 6 weeks. Participants in stratum II were analyzed to evaluate the LDL-C lowering efficacy with the additional of ezetimibe 10 mg to rosuvastatin 10 mg daily for 6 weeks compared with doubling the baseline dose to rosuvastatin 20 mg daily for 6 weeks.
Time frame: 6 weeks of treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Number of Participants in Each Stratum Who Reached Their Target LDL-C Level | 54 participants |
| Rosuvastatin (10 or 20 mg) | Number of Participants in Each Stratum Who Reached Their Target LDL-C Level | 30 participants |
| Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) | Number of Participants in Each Stratum Who Reached Their Target LDL-C Level | 76 participants |
| Rosuvastatin 20 mg (Stratum II) | Number of Participants in Each Stratum Who Reached Their Target LDL-C Level | 37 participants |
p-value: <0.00195% CI: [1.7, 5.8]Logistic Regression
p-value: <0.00195% CI: [3.4, 12.3]Logistic Regression
Secondary
Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl
Participants in stratum I and in stratum II who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe to rosuvastatin (5 or 10 mg)daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg).
Time frame: 6 weeks of treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl | 31 participants |
| Rosuvastatin (10 or 20 mg) | Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl | 12 participants |
| Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) | Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl | 65 participants |
| Rosuvastatin 20 mg (Stratum II) | Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl | 26 participants |
Comparison: Stratum Ip-value: <0.00195% CI: [2.2, 11.8]Logistic Regression
Comparison: Stratum IIp-value: <0.00195% CI: [5.2, 24.8]Logistic Regression
Secondary
Number of Participants Who Reached Their Target LDL-C Level
Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment.
Time frame: 6 weeks of treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Number of Participants Who Reached Their Target LDL-C Level | 130 participants |
| Rosuvastatin (10 or 20 mg) | Number of Participants Who Reached Their Target LDL-C Level | 67 participants |
p-value: <0.00195% CI: [2.9, 6.9]Logistic Regression
Secondary
Number of Participants Who Reached the LDL-C Level of <70 mg/dl
Participants across all strata who reached the LDL-C Level of \<70 mg/dl after the addition of ezetimibe 10 mg to rosuvastatin (5 or 10 mg) daily for 6 weeks compared with doubling the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
Time frame: 6 weeks of treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Number of Participants Who Reached the LDL-C Level of <70 mg/dl | 96 participants |
| Rosuvastatin (10 or 20 mg) | Number of Participants Who Reached the LDL-C Level of <70 mg/dl | 38 participants |
p-value: <0.00195% CI: [4.6, 14]Logistic Regression
Secondary
Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum
The percent change from baseline in LDL-C (mg/dL) after 6 weeks of treatment by stratum I and stratum II in participants who were administered with ezetimibe 10 mg to rosuvastatin (5 or 10 mg) in comparison with the doubling of the baseline dose of rosuvastatin (10 or 20 mg) daily for 6 weeks.
Time frame: Baseline to 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum | -18.57 percentage change | Standard Deviation 26.35 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum | -4.96 percentage change | Standard Deviation 22.42 |
| Rosuvastatin 10 mg + Ezetimibe 10 mg (Stratum II) | Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum | -24.00 percentage change | Standard Deviation 23.86 |
| Rosuvastatin 20 mg (Stratum II) | Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum | -6.07 percentage change | Standard Deviation 27.65 |
p-value: <0.00195% CI: [-18.95, -5.67]Longitudinal Data Analysis (LDA)
p-value: <0.00195% CI: [-23.92, -10.99]Longitudinal Data Analysis (LDA)
Secondary
Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels
Participants who were analyzed to assess the Total Cholesterol (TC), Triglycerides, High-Density Lipoprotein Cholesterol, Non High-Density Lipoprotein Cholesterol, LDL Cholesterol/HDL Cholesterol, Total Cholesterol/HDL Cholesterol, Non-HDL Cholesterol/HDL Cholesterol, Apolipoprotein B (Apo B), Apolipoprotein A-I (Apo A-I), Apolipoprotein B/Apo A-I, high-sensitivity C-reactive protein (hs-CRP)levels after 6 weeks of treatment.
Time frame: Baseline to 6 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Non High-Density Liproprotein Cholesterol | -17.59 percentage change | Standard Deviation 23.55 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Non-HDL Cholestrol/HDL Cholesterol | -14.51 percentage change | Standard Deviation 35.39 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | High-Density Lipoprotein Cholesterol | -0.67 percentage change | Standard Deviation 15.51 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Apolipoprotein B (Apo B) | -14.31 percentage change | Standard Deviation 18.61 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | LDL Cholesterol/HDL Cholesterol | -19.48 percentage change | Standard Deviation 27.63 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Apolipoprotein A-I (Apo A-I) | -1.44 percentage change | Standard Deviation 12.49 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Triglycerides | -5.96 percentage change | Standard Deviation 36.45 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Apolipoprotein B/Apo A-I | -11.98 percentage change | Standard Deviation 20.84 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Total Cholesterol/HDL Cholesterol | -10.57 percentage change | Standard Deviation 25.87 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | hs-C-Reactive Protein | -13.98 percentage change | Standard Deviation 72.19 |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Total Cholesterol (TC) | -13.00 percentage change | Standard Deviation 17.51 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | hs-C-Reactive Protein | -12.82 percentage change | Standard Deviation 73.08 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Total Cholesterol (TC) | -3.76 percentage change | Standard Deviation 14.35 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Triglycerides | -3.60 percentage change | Standard Deviation 32.83 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | High-Density Lipoprotein Cholesterol | 2.18 percentage change | Standard Deviation 13.38 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Non High-Density Liproprotein Cholesterol | -5.29 percentage change | Standard Deviation 21.2 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | LDL Cholesterol/HDL Cholesterol | -6.18 percentage change | Standard Deviation 27.82 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Total Cholesterol/HDL Cholesterol | -4.40 percentage change | Standard Deviation 18.27 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Non-HDL Cholestrol/HDL Cholesterol | -5.31 percentage change | Standard Deviation 26.63 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Apolipoprotein B (Apo B) | -4.25 percentage change | Standard Deviation 17.56 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Apolipoprotein A-I (Apo A-I) | 1.06 percentage change | Standard Deviation 11.56 |
| Rosuvastatin (10 or 20 mg) | Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels | Apolipoprotein B/Apo A-I | -4.11 percentage change | Standard Deviation 19.61 |
Comparison: Total Cholesterol (mg/dL)p-value: <0.00195% CI: [-11.59, -5.71]Longitudinal Data Analysis
Comparison: Triglycerides (mg/dL)p-value: 0.30695% CI: [-9.04, 2.84]Longitudinal Data Analysis
Comparison: High-Density Lipoprotein Cholesterolp-value: 0.11195% CI: [-4.79, 0.49]Longitudinal Data Analysis
Comparison: Non High-Density Liproprotein Cholesterolp-value: <0.00195% CI: [-16.1, -7.86]Longitudinal Data Analysis
Comparison: LDL Cholesterol/HDL Cholesterolp-value: <0.00195% CI: [-18.36, -8.13]Longitudinal Data Analysis
Comparison: Total Cholesterol/HDL Cholesterolp-value: 0.00295% CI: [-10.53, -2.36]Longitudinal Data Analysis
Comparison: Non-HDL Cholestrol/HDL Cholesterolp-value: 0.00195% CI: [-15.3, -3.75]Longitudinal Data Analysis
Comparison: Apolipoprotein B (Apo B)p-value: <0.00195% CI: [-12.74, -6.08]Longitudinal Data Analysis
Comparison: Apolipoprotein A-I (Apo A-I)p-value: 0.10295% CI: [-3.99, 0.36]Longitudinal Data Analysis
Comparison: Apolipoprotein B/Apo A-Ip-value: <0.00195% CI: [-11.25, -3.83]Longitudinal Data Analysis
Comparison: hs-C-Reactive Proteinp-value: 0.86195% CI: [-13.13, 10.97]Longitudinal Data Analysis